Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2001 Nov;60(Suppl 3):iii2–iii5. doi: 10.1136/ard.60.90003.iii2

Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)

D FURST, E KEYSTONE, F BREEDVELD, J KALDEN, J SMOLEN, C ANTONI, G BURMESTER, L CROFFORD, A KAVANAUGH
PMCID: PMC1766671  PMID: 11890647

Full Text

The Full Text of this article is available as a PDF (81.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bathon J. M., Martin R. W., Fleischmann R. M., Tesser J. R., Schiff M. H., Keystone E. C., Genovese M. C., Wasko M. C., Moreland L. W., Weaver A. L. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 Nov 30;343(22):1586–1593. doi: 10.1056/NEJM200011303432201. [DOI] [PubMed] [Google Scholar]
  2. Elliott M. J., Maini R. N., Feldmann M., Kalden J. R., Antoni C., Smolen J. S., Leeb B., Breedveld F. C., Macfarlane J. D., Bijl H. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994 Oct 22;344(8930):1105–1110. doi: 10.1016/s0140-6736(94)90628-9. [DOI] [PubMed] [Google Scholar]
  3. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Bijl H., Woody J. N. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet. 1994 Oct 22;344(8930):1125–1127. doi: 10.1016/s0140-6736(94)90632-7. [DOI] [PubMed] [Google Scholar]
  4. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F. M., Walker J., Bijl H., Ghrayeb J. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993 Dec;36(12):1681–1690. doi: 10.1002/art.1780361206. [DOI] [PubMed] [Google Scholar]
  5. Furst D. E., Keystone E., Maini R. N., Smolen J. S. Recapitulation of the round-table discussion--assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 1999 Nov;38 (Suppl 2):50–53. [PubMed] [Google Scholar]
  6. Garrison L., McDonnell N. D. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis. 1999 Nov;58 (Suppl 1):I65–I69. doi: 10.1136/ard.58.2008.i65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hanauer S. B. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999 Sep;13 (Suppl 4):16–38. doi: 10.1046/j.1365-2036.1999.00027.x. [DOI] [PubMed] [Google Scholar]
  8. Harriman G., Harper L. K., Schaible T. F. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment. Ann Rheum Dis. 1999 Nov;58 (Suppl 1):I61–I64. doi: 10.1136/ard.58.2008.i61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jones R. E., Moreland L. W. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis. 1999;48(3):1–4. [PubMed] [Google Scholar]
  10. Kavanaugh A. F. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am. 1998 Aug;24(3):593–614. doi: 10.1016/s0889-857x(05)70028-4. [DOI] [PubMed] [Google Scholar]
  11. Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Weisman M., Emery P., Feldmann M. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594–1602. doi: 10.1056/NEJM200011303432202. [DOI] [PubMed] [Google Scholar]
  12. Lovell D. J., Giannini E. H., Reiff A., Cawkwell G. D., Silverman E. D., Nocton J. J., Stein L. D., Gedalia A., Ilowite N. T., Wallace C. A. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000 Mar 16;342(11):763–769. doi: 10.1056/NEJM200003163421103. [DOI] [PubMed] [Google Scholar]
  13. Maini R. N., Breedveld F. C., Kalden J. R., Smolen J. S., Davis D., Macfarlane J. D., Antoni C., Leeb B., Elliott M. J., Woody J. N. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998 Sep;41(9):1552–1563. doi: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  14. Markham A., Lamb H. M. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs. 2000 Jun;59(6):1341–1359. doi: 10.2165/00003495-200059060-00010. [DOI] [PubMed] [Google Scholar]
  15. Moreland L. W., Baumgartner S. W., Schiff M. H., Tindall E. A., Fleischmann R. M., Weaver A. L., Ettlinger R. E., Cohen S., Koopman W. J., Mohler K. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997 Jul 17;337(3):141–147. doi: 10.1056/NEJM199707173370301. [DOI] [PubMed] [Google Scholar]
  16. Moreland L. W., Margolies G., Heck L. W., Jr, Saway A., Blosch C., Hanna R., Koopman W. J. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol. 1996 Nov;23(11):1849–1855. [PubMed] [Google Scholar]
  17. Moreland L. W., Schiff M. H., Baumgartner S. W., Tindall E. A., Fleischmann R. M., Bulpitt K. J., Weaver A. L., Keystone E. C., Furst D. E., Mease P. J. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16;130(6):478–486. doi: 10.7326/0003-4819-130-6-199903160-00004. [DOI] [PubMed] [Google Scholar]
  18. Shekelle P. G., Woolf S. H., Eccles M., Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999 Feb 27;318(7183):593–596. doi: 10.1136/bmj.318.7183.593. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES